Gavreto (pralsetinib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

Image 1-Gavreto (pralsetinib)
Gavreto™ (pralsetinib) is a targeted therapy to treat adult patients with RET fusion-positive non-small cell lung cancer (NSCLC). Credit: Roche.